Rating Change
Chardan Capital analysts reiterated a Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on July 01, 2026.
reiterateNASDAQ:EYPT
Chardan Capital Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Rating Change Chardan Capital analysts reiterated a Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on July 01, 2026. Market Context EyePoint Pharmaceuticals, Inc.
Market Context
EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $14.91 with a market capitalization of $1.1B. The stock has gained 48.3% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for EyePoint Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 01, 2026 | Chardan Capital | Buy | N/A |
| Jun 24, 2026 | Guggenheim | Buy | N/A |
| May 07, 2026 | RBC Capital | Outperform | N/A |
| Mar 09, 2026 | Citigroup | Buy | N/A |
| Mar 05, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page
Frequently Asked Questions
What does a Buy rating mean for EYPT?
A Buy rating from Chardan Capital reflects the analyst's outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EYPT forecast page.